{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:05:13Z","timestamp":1789578313252,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["STG1\/M-405\/25-N"],"award-info":[{"award-number":["STG1\/M-405\/25-N"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["AoE\/E-407\/24-N"],"award-info":[{"award-number":["AoE\/E-407\/24-N"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.05.009","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T20:50:56Z","timestamp":1780001456000},"page":"895-910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["EZH2 Inhibition Remodels Cell States and Enhances EGFRi Sensitization in Bladder Cancer"],"prefix":"10.1016","volume":"9","author":[{"given":"Hongda","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyue","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Vincy","family":"Wing Sze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoxiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Ho","family":"Yin Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Ka-Fung","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Fai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinglan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9361-2342","authenticated-orcid":false,"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.05.009_b0005","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2026.05.009_b0010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.009_b0015","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.euo.2026.05.009_b0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor evolution and drug response in patient-derived organoid models of bladder cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.euo.2026.05.009_b0025","article-title":"Patient-derived bladder cancer organoids as a valuable tool for understanding tumor biology and developing personalized treatment","volume":"12","author":"Zhao","year":"2025","journal-title":"Adv Sci"},{"key":"10.1016\/j.euo.2026.05.009_b0030","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2026.05.009_b0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41587-020-00762-x","article-title":"The organoid cell atlas","volume":"39","author":"Bock","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.euo.2026.05.009_b0040","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1158\/1078-0432.CCR-05-1047","article-title":"Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder","volume":"11","author":"Raman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.05.009_b0045","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo8043","article-title":"Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma","volume":"8","author":"Piunti","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.euo.2026.05.009_b0050","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.05.009_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118106","article-title":"Recent update on the development of EZH2 inhibitors and degraders for cancer therapy","volume":"299","author":"Tang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.euo.2026.05.009_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1233953","article-title":"Non-canonical functions of EZH2 in cancer","volume":"13","author":"Zimmerman","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2026.05.009_b0065","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.euo.2026.05.009_b0070","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41592-019-0433-8","article-title":"MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices","volume":"16","author":"McGinnis","year":"2019","journal-title":"Nat Methods"},{"key":"10.1016\/j.euo.2026.05.009_b0075","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature19360","article-title":"Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition","volume":"537","author":"Dahl","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.euo.2026.05.009_b0080","article-title":"Single-cell RNA sequencing reveals a fibroblast gene signature that promotes T-cell infiltration in muscle-invasive bladder cancer","volume":"8","author":"Liu","year":"2025","journal-title":"Commun Biol"},{"key":"10.1016\/j.euo.2026.05.009_b0085","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11899-018-0466-6","article-title":"Emerging EZH2 inhibitors and their application in lymphoma","volume":"13","author":"Lue","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.euo.2026.05.009_b0090","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41467-017-00612-6","article-title":"NFATc1 controls the cytotoxicity of CD8+ T cells","volume":"8","author":"Klein-Hessling","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.05.009_b0095","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2026.05.009_b0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.euo.2026.05.009_b0105","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","article-title":"Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer","volume":"184","author":"Raghavan","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.euo.2026.05.009_b0110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Ben-David","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.euo.2026.05.009_b0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-018-0024-3","article-title":"Intra-tumour diversification in colorectal cancer at the single-cell level","volume":"556","author":"Roerink","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.euo.2026.05.009_b0120","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.05.009_b0125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e16579","article-title":"Chemotherapy regimen and cisplatin dose effects on survival in neoadjuvant treatment of urothelial muscle-invasive bladder cancer","volume":"43","author":"Malik","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.05.009_b0130","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41420-024-02031-1","article-title":"Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1\/EZH2-mediated downregulation of REST","volume":"10","author":"Zheng","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.euo.2026.05.009_b0135","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1038\/s41467-018-06177-2","article-title":"Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.05.009_b0140","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.molcel.2020.10.033","article-title":"Impact of lineage plasticity to and from a neuroendocrine phenotype on progression and response in prostate and lung cancers","volume":"80","author":"Rubin","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.euo.2026.05.009_b0145","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41586-024-08150-0","article-title":"Progressive plasticity during colorectal cancer metastasis","volume":"637","author":"Moorman","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.euo.2026.05.009_b0150","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2026.05.009_b0155","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/2159-8290.CD-22-1441","article-title":"Resistance to selective FGFR-inhibitors in driven urothelial cancer","volume":"13","author":"Facchinetti","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2026.05.009_b0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","article-title":"Emerging strategies to overcome resistance to third-generation EGFR inhibitors","volume":"15","author":"Shi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.euo.2026.05.009_b0165","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","article-title":"Combining epigenetic drugs with other therapies for solid tumours \u2013 past lessons and future promise","volume":"17","author":"Morel","year":"2020","journal-title":"Nat Rev Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:46:10Z","timestamp":1789577170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931126001379"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.05.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EZH2 Inhibition Remodels Cell States and Enhances EGFRi Sensitization in Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}